Age Old Question

by EpicentRx | Oct 30, 2024 | Media

published in the November edition of PharmaTimes

Endometriosis: An immune disease

by EpicentRx | Oct 30, 2024 | Media

published in Drug Discovery & Development

EpicentRx To Present Compelling Phase 2 Clinical Data on AdAPT-001 Plus a Checkpoint Inhibitor in PD-1/L1 Resistant Tumors at the SITC 39th Annual Meeting

by EpicentRx | Oct 28, 2024 | 2024, Press Releases

The combination AdAPT-001 + a checkpoint inhibitor achieved high durable overall response rates and an 8 month+ PFS in patients who progressed on checkpoint inhibitors and chemotherapy TORREY PINES, Calif., Oct. 28, 2024 – EpicentRx, a clinical-stage biopharmaceutical...

Words of Wisdom from Q3

by EpicentRx | Oct 9, 2024 | Company Updates

Let It Be GIFfrom The Beatles GIFs Set to the tune of the Beatles’ song, “Let It Be”, we present words of wisdom from the Third Quarter (Q3). These words of wisdom were not whispered, as in the “Let It Be” song lyrics, but spoken confidently with precise experimental...

Bizzaro Cancer World

by EpicentRx | Oct 4, 2024 | Media